Inotsume N - Search Results

1

[Establishment of pharmaceutical management for patient care during lung cancer chemotherapy and its quantitative evaluation].

Hayakawa T, Yamanouchi K, Hirohata T, Totsu S, Makino A, Sato H, Fujita A, Sekine K, Inotsume N. Hayakawa T, et al. Among authors: inotsume n. Yakugaku Zasshi. 2005 May;125(5):405-16. doi: 10.1248/yakushi.125.405. Yakugaku Zasshi. 2005. PMID: 15863972 Free article. Japanese.

2

[Comparison of dexamethasone 8 mg and 16 mg for the prevention of acute and delayed cisplatin-induced emesis in patients with lung cancer].

Hayakawa T, Sato M, Hirohata T, Totsu S, Makino A, Wada Y, Sato H, Inotsume N, Fujita A, Sekine K. Hayakawa T, et al. Among authors: inotsume n. Yakugaku Zasshi. 2006 Jan;126(1):61-6. doi: 10.1248/yakushi.126.61. Yakugaku Zasshi. 2006. PMID: 16394651 Free article. Japanese.

3

[Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].

Hayakawa T, Sato M, Konaka M, Makino A, Hirohata T, Totsu S, Wada Y, Sato H, Inotsume N, Fujita A, Sekine K. Hayakawa T, et al. Among authors: inotsume n. Gan To Kagaku Ryoho. 2006 May;33(5):633-8. Gan To Kagaku Ryoho. 2006. PMID: 16685162 Japanese.

4

Pharmacoeconomic evaluation of anti-hyperlipidemic agent fenofibrate.

Hayakawa T, Shimoyama K, Sekiya S, Sekiguchi M, Inotsume N. Hayakawa T, et al. Among authors: inotsume n. Yakugaku Zasshi. 2002 Dec;122(12):1145-51. doi: 10.1248/yakushi.122.1145. Yakugaku Zasshi. 2002. PMID: 12510391 Free article. Clinical Trial.

5

[Studies on the risk factors for fenofibrate-induced elevation of liver function tests].

Hayakawa T, Hayashi A, Miyakawa M, Shimoyama K, Sekiya S, Sekiguchi M, Inotsume N. Hayakawa T, et al. Among authors: inotsume n. Yakugaku Zasshi. 2002 Feb;122(2):169-75. doi: 10.1248/yakushi.122.169. Yakugaku Zasshi. 2002. PMID: 11857958 Free article. Japanese.

6

Effects of absorption rate on the pre-systemic chiral inversion of ibuprofen in rabbits.

Doki K, Hayakawa T, Lin W, Yanaguimoto H, Ding G, Inotsume N. Doki K, et al. Among authors: inotsume n. J Pharm Pharmacol. 2003 Aug;55(8):1091-7. doi: 10.1211/0022357021404. J Pharm Pharmacol. 2003. PMID: 12956898

7

Losartan competitively inhibits CYP2C8-dependent paclitaxel metabolism in vitro.

Mukai Y, Toda T, Hayakawa T, Eliasson E, Rane A, Inotsume N. Mukai Y, et al. Among authors: inotsume n. Biol Pharm Bull. 2014;37(9):1550-4. doi: 10.1248/bpb.b14-00366. Biol Pharm Bull. 2014. PMID: 25177037 Free article.

8

Effects of Angiotensin II Receptor Blockers on Metabolism of Arachidonic Acid via CYP2C8.

Senda A, Mukai Y, Toda T, Hayakawa T, Yamashita M, Eliasson E, Rane A, Inotsume N. Senda A, et al. Among authors: inotsume n. Biol Pharm Bull. 2015;38(12):1975-9. doi: 10.1248/bpb.b15-00577. Biol Pharm Bull. 2015. PMID: 26632190 Free article.

9

Pharmacokinetic interaction of ibuprofen enantiomers in rabbits.

Lin W, Hayakawa T, Yanaguimoto H, Kuzuba M, Obara T, Ding G, Cui F, Inotsume N. Lin W, et al. Among authors: inotsume n. J Pharm Pharmacol. 2004 Mar;56(3):317-21. doi: 10.1211/0022357022845. J Pharm Pharmacol. 2004. PMID: 15025856

10

Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.

Mukai Y, Senda A, Toda T, Hayakawa T, Eliasson E, Rane A, Inotsume N. Mukai Y, et al. Among authors: inotsume n. Basic Clin Pharmacol Toxicol. 2015 Jun;116(6):493-8. doi: 10.1111/bcpt.12355. Epub 2014 Dec 23. Basic Clin Pharmacol Toxicol. 2015. PMID: 25424246 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page